Loading patent…
AssigneeMedicago Inc.
InventorsPierre-Olivier LAVOIE, Aurelien LORIN, Alain DOUCET, Marc-Andre D'AOUST, Manon COUTURE
Estimating the term…
The present invention relates to the production of modified influenza vial proteins in plants. More specifically, the present invention relates to producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA). The H A protein may comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acid encoding the modified H A protein. Furthermore methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.
1-43. (canceled)
A nucleic acid comprising a nucleotide sequence encoding a modified influenza H1 hemagglutinin (HA) protein, the HA protein comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence, said at least one substitution being at one or more than one amino acid corresponding to amino acid at position 390, 429, 97, or 374 of H1 A/Michigan/45/15 HA.
A modified influenza H1 hemagglutinin (HA) protein, the HA protein comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence, said at least one substitution being at one or more than one amino acid corresponding to amino acid at position 390, 429, 97, or 374 of H1 A/Michigan/45/15 HA.
Dependencies are inferred from the claim text.